A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
Ontology highlight
ABSTRACT: The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.
DISEASE(S): Colorectal Cancer,Advanced Solid Tumors,Gastric Cancer,Cancer
PROVIDER: 2189885 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA